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Introduction
Human immunodeficiency virus (HIV) as the etiological agent of  
acquired immunodeficiency syndrome (AIDS) causes progressive 
impairment of  the body’s cellular immune system thus resulting 
in increased susceptibility to infections [11, 24]. Currently, two 
immunological types are known, HIV-1 and HIV-2. HIV-1 is an 
enveloped RNA retrovirus which causes most HIV infections 
worldwide and HIV-2 which is found mainly in West Africa [6].
HIV is transmitted by direct inoculation into the bloodstream; 
otherwise, after contact and attachment through mucosal 
surfaces it preferentially infects CD4+ cells. However, HIV also 
attaches other co-receptors such as CCR5 and CXCR4 lying on 
the cell surface and infect that cell. Within the cell, viral RNA is 
transcribed to DNA by the HIV reverse transcriptase. Also, the 
HIV protease enzyme cleaves the viral polyprotein to form mature 
viral particles, which are then released from cells to infect other 
cells [25]. HIV/AIDS incident was formally discovered in Nigeria 
in 1986 and since then the prevalence rate has been increasing in 
the country. It increased from 1.6% to 5.8% in the period between 
1991 to 2001. The estimated number of  affected person in 2006 
was 2.99 million with female constituting about 58% [26]. 
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Abstract
Background: Previous reports showed lack of  consensus on the possible etiology of  coronary artery disease (CAD) be-
tween HIV-treatment with highly active antiretroviral therapy (HAART) and HIV-infection in particular. The aim of  this 
study was to find out correlations of  HIV-treatment and HIV-infection with CAD risk. 
Method: One hundred and twenty (120) participants involving HIV-patients on treatment (n = 40), treatment-naïve (n = 
40) and equal number of  age- and sex-matched controls were enrolled. The total cholesterol, triglycerides and lipoprotein 
(HDL-C) were analyzed using spectrophotometry. The LDL-C was calculated using Friedewald equation, TC/HDL-C and 
LDL-C/HDL-C ratios were also calculated. The CD4+ cell count was determined using flow cytometry. 
Result: The mean plasma total cholesterol levels in patients’ groups on treatment and treatment-naïve were significantly 
reduced when compared with controls, but the mean triglyceride levels for both treatment and the treatment-naïve groups 
were significantly increased when compared with controls. However, HDL-C and LDL-C values for patients on HAART 
and the treatment-naive were significantly reduced when compared with controls respectively. The CAD risk predictors, 
LDL-c and TC/HDL-C ratio, were significantly increased in patients on HAART when compared with the treatment-naive. 
The mean CD4+ cell count in treatment-naive was significantly lowered against both groups for treatment and controls.
Conclusion: In this present study, abnormal lipid profile was associated with both HIV-infection and HAART-treatment. 
However, TC/HDL-C ratio, the strong predictor of  CAD events in metabolic disorder was markedly high in HAART-
treatment and the associated difference may threaten higher risk for cardiovascular disease (CVD) during treatment.
Keywords: Coronary Artery Disease; Dyslipidemia; Highly Active Antiretroviral Therapy; Human Immunodeficiency 
Virus.
Kamoru AA, Japhet OM, Adetunji AD, Akinlawon AA, Musa MA, et al., (2017) CD4+ Cell Count, Lipid And Lipoprotein Levels In Hiv Patients On Drug Treatment. Int J AIDS 
Res. 4(1), 140-146. 141
 OPEN ACCESS                                                                                                                                                                                  http://scidoc.org/IJHR.php
Some studies [23, 46, 47] indicated that Nigeria has the third 
highest number of  people estimated to be living with HIV/
AIDS in the world (3.6 million as of  the end of  2003), after South 
Africa and India. HIV prevalence is high among young people 
in Nigeria, especially young women [46-48]. Among those ages 
15-24, the estimated number of  young women living with HIV/
AIDS was almost twice that of  young men in the country [46, 
47]. In 2003, 290,000 children in Nigeria were estimated to be 
living with HIV/AIDS [23]. Nigeria has the highest number of  
AIDS orphans in sub-Saharan Africa (an estimated 1.8 million 
in 2003). There is significant variation in HIV prevalence rates 
across the country with the hardest hit states being Benue and 
Cross River [47]. In 1987, after 6 years of  watching people die, 
a new treatment emerged and was hailed as the first huge step in 
beating HIV/AIDS. The drug Retrovir (AZT, Zidovudine) was 
FDA approved and began to be used in high doses to treat people 
infected with HIV [24].
A decision to start treatment is based primarily on the CD4 count 
level and HIV viral load, and secondarily on the readiness of  the 
patient to accept and adhere to lifelong treatment. In general, 
treatment is recommended for those patients with a CD4 count < 
350/mm3 [51]. Most HIV infected people require HIV treatment 
at some point during infection with the aid of  antiretroviral 
therapy (ART). Antiretroviral drugs are a group of  drugs that 
inhibit the reproduction of  retroviruses-viruses composed of  
RNA rather than DNA [27].
Six different classes of  antiretroviral agents (AVR) have been 
approved by the U.S FDA. They include: nucleoside reverse 
transcriptase inhibitors (NRTIs); non-nucleoside reverse 
transcriptase inhibitors (NNRTIs); Protease inhibitors (PIs); 
integrase inhibitors; fusion inhibitors (or entry inhibitors) and 
CCR5 receptor antagonists [6]. Several national and international 
expert panels have established numerous HIV treatment guidelines. 
Recommended regimens usually include three different ARV 
agents in combination, usually from two classes such as 1NNRTI 
+ 2NRTIs or 1PI + 2NRTIs [31]. The Front Line Drug Regimen 
(FLDR) mostly used in the twenty-seven treatment sites across 
the country is Zidovudine + Lamivudine + Nevirapine (2NRTIs 
+1NNRTI) as a combined therapy, Efavirenz or Abacavir is used 
in place of  Nevirapine. In some centers depending on the status 
- HIV Post Exposure Prophylaxis (PEP), Prevention of  mother-
to-child-transmission (PMTCT), pregnancy or in children, this 
replacement is usually necessary [40].
Despite the efforts of  various agencies and supports from 
international bodies in combating the spread as well as death 
from HIV/AIDS, patients on ART still continue to die as a result 
of  side effects, particularly chronic toxicities [2, 35, 40]. The 
widespread use of  protease inhibitors (PIs) and nucleoside and 
nucleotide inhibitors as antiretroviral drugs and their long-term 
administration has been associated with secondary metabolic 
adverse effects in some studies [7, 28]. Dyslipidemia, including 
hypertriglyceridemia or combined hyperlipidemia, as well as 
glucose intolerance and hyperinsulinism have been repeatedly 
reported [1, 3, 9, 32, 41]. In the meantime, the mechanisms that 
cause those metabolic alterations are not fully understood and are 
actively debated.
Nevertheless, these metabolic troubles are suspected to constitute 
risk factors for atherosclerosis as well as coronary artery disease 
(CAD) [7]. In most reports, the dyslipidemia with antiretroviral 
therapy has been assessed from measurements of  lipids, 
cholesterol distribution, and of  major apolipoproteins (Apos) [3, 
32]. Increased levels of  complex lipoparticles, containing Apoc-
111 and/or Apo E, and Apo B have been found in CAD patients 
[15]. 
Occurrence of  lipodystrophy (LD) has also been commonly 
described on antiretroviral treatment, the most frequent aspect 
associating wastage of  the face and limbs, and an increase in 
abdominal fat [9, 10, 7, 29]. Despite the elevated prevalence of  
this LD (between 30% and 70% among studies), the factors or 
metabolic indices associated with its developments have not yet 
been clearly elucidated [7].
On the contrary, several studies have demonstrated that many 
factors may contribute to the pathogenesis of  dyslipideamia, an 
increased synthesis of  triglycerides (TGs) and very low - density 
lipoproteins (VLDLs), a lipolysis defect modulating both the 
synthesis and catabolism of  VLDLs [4, 27]. Dyslipideamia as an 
established risk factor of  cardiovascular diseases has therefore been 
reported in HIV/AIDS. However, the incidence of  cardiovascular 
disease in HIV-infected patients receiving antiretroviral therapy 
is low. Although, the risk of  cardiovascular disease is increased 
when compared with that in uninfected persons. This fact is 
substantially due to a higher prevalence of  underlying traditional 
cardiovascular risk factors that are mostly host dependent and 
HIV contributing both directly through immune activation and 
inflammation, and indirectly through immunodeficiency [28].
Also, against the previous studies of  antiretroviral treatment some 
authors [2, 19] argued that cardiovascular complications in the 
course of  human immunodeficiency virus (HIV) infection are 
multifactorial and may be caused by the virus itself  or by the 
related opportunistic infections and neoplasms and that the course 
of  vascular disease may be accelerated in HIV infected patients 
because of  atherogenesis stimulated by HIV-infected monocyte-
macrophages, possibly via leukocyte adhesion or arteritis. 
In view of  the conflicting reports aforementioned, this study 
is designed to investigate and distinguish the effect of  HIV 
infection from its treatment on lipid profile in HIV-infected 
subjects. Meanwhile, with the use of  potent ART in patients 
with HIV disease, so many researchers have noted changes in 
lipid parameters and glucose homeostasis [2, 32]. However, these 
effects have been difficult to interpret because of  the varied 
demographic and treatment characteristics of  the cohorts and 
the complexity of  differentiating the effect of  HIV disease from 
that of  the drugs used in its treatment. This study is designed to 
explore the issues aforementioned by clarifying the actual cause 
of  dyslipidemia between the HIV disease and its ART treatment.
Materials and Method
This study was conducted at Ladoke Akintola University of  
Technology Teaching Hospital, LAUTECH, Osogbo located in 
the core of  southwestern, Nigeria.
Subject Selection and Sample Size
One hundred and twenty (120) participants were enrolled in this 
study. Consecutive HIV-positive patients attending the hospital 
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both for follow-up consultation and the newly diagnosed patients 
between the ages of  18-55 years were randomly selected. To get 
reference control values for all investigated parameters, subjects 
of  both sexes with age related and living in the same geographical 
area were also recruited. The study commenced after the 
proposal had been reviewed and approved by LAUTECH Ethical 
Committee with the assistance of  the laboratory scientist in-
charge. The subjects were grouped as follows;
1. Fourty HIV-infected subjects on treatment for three months 
and above, {M=20, F=20}. 
2. Fourty newly diagnosed HIV infected subjects, treatment-
naïve, {M= 16, F= 24}.
3. Fourty HIV-negative subjects, but living in the same 
geographical area, {M= 17, F= 23}.
Inclusion and exclusion criteria
Subjects with the following manifestations were excluded based 
on their clinical history (and diagnosis); DM (Diabetes Mellitus), 
jaundice, hepatitis, hypothyroidism, hypertensions and nephrotic 
syndrome. Likewise, participants using contraceptives and 
corticosteroid therapy were equally excluded.
Laboratory methods
Ten milliliters (10mls) of  venous blood was collected from the 
cubital vein of  each subject using a sterile needle and syringe into 
an appropriate bottle (EDTA-bottle). The plasma extracted by 
centrifugation for 10 minutes at 4000 rpm into plain bottle and 
stored at -20°C until the time of  analysis.
Lipid profile: The plasma concentrations of  total cholesterol, 
triglyceride, high density lipoprotein, total cholesterol were 
measured using spectrophotometry method. 
Plasma cholesterol was estimated by an enzymatic method [44]. 
Cholesterol was determined after an enzymatic hydrolysis and 
oxidation. The mixture was incubated at room temperature for 
ten minutes after which the absorbance was read at wavelength 
of  500nm. Plasma triglyceride was estimated using the enzymatic 
method of  [8] Triglyceride was determined after enzymatic 
hydrolysis with lipases. The mixtures were mixed thoroughly 
and then incubated for 10 minutes at room temperature. The 
absorbance was then read at wavelength of  500nm. 
HDL-Cholesterol was estimated using a precipitated method 
[5]. In the presence of  phosphotungstic acid and magnesium 
chloride, LDL, VLDL and chylomicrons were precipitated on 
centrifugation for 10 minutes at 4000 rpm. 
The supernatant was separated immediately and the cholesterol 
content was determined. Centrifugation left with only the HDL 
in the supernatant; HDL-c fraction freed as supernatant was 
taken as sample containing HDL fraction which was successively 
determined using cholesterol assay method.
Calculation: After the estimation of  total cholesterol, TG and 
HDL-C as stated above, LDL-C was calculated using Friedewald 
formula stated as follows; LDL-C = Total cholesterol-(TG/5 + 
HDL).
This was applicable since the concentration of  cholesterol and 
TG was less than 400mg/dl [16]. Similarly, TC/HDL-C and 
LDL-C/HDL-C ratios were also calculated.
CD4+ cell count: CD 4 T-cells were counted using a method of  
flow cytomery. Analysis with the aid of  Partec flow cytometer by 
TUV Rheinland.
Flow cytometry was a useful method by which cell or micro 
particles in suspension were differentiated and counted according 
to cell size, fluorescence emission and internal structure [19].
Statistical Analysis
Results were reported as means (± SE) with analysis of  variance 
(ANOVA). Means were also analyzed using Post Hoc test to 
compare the significant variables. Pearson’s correlation coefficient 
(r) was used to determine the relationship between means of  the 
variables. Results were regarded as significant at P < 0.05.
Results and Interpretation
Table 1 shows analysis of  variance (ANOVA) of  the means (± 
SEM) of  lipid, lipoparticle levels, CD4 cell count and age for 
HIV+ on ART treatment (group 1), HIV+ treatment naïve (group 
2) and the controls (group 3). The mean total cholesterol value 
(mmol/L) in people with HIV+ on treatment (3.69 ± 0.07) was 
significantly lowered (p < 0.05) compared with the controls (5.32 
±0.09). Whereas, there was a significant increase in this mean 
value of  HIV+ on treatment (3.69 + 0.07) when compared with 
treatment naïve (2.43 ± 0.04). On the contrary, the triglyceride 
mean values (mmol/L) in people with HIV+ on treatment (1.87 
± 0.03) and HIV+ patients treatment naïve (1.97 ± 0.02) were 
both significantly increased (p < 0.05) compared with the controls 
(1.18 ± 0.05). But the mean triglyceride value of  HIV+ treatment 
naïve (1.97 ± 0.02) was significantly higher than that of  mean 
value of  HIV+ on treatment (1.87 ± 0.03).
However, the mean values of  HDL-C (mmol/L) in people with 
HIV+ on treatment (0.99 ± 0.04) and HIV+ patients treatment 
naïve (0.85 ± 0.02) were significantly lowered (p < 0.05) compared 
with controls (1.43 ± 0.04). Nevertheless, the mean value of  
HDL-C (mmol/L) in people with HIV+ on treatment (0.99 ± 
0.04) was significantly higher compared with HIV+ treatment 
naïve (0.85 ± 0.02). LDL-C mean values (mmol/L) in people with 
HIV+ on treatment (2.12 ± 0.08) and HIV+ patients treatment 
naïve (0.60 ± 0.03) were significantly lowered (p < 0.05) when 
compared with controls (3.32 ± 0.09). But there was a significant 
increase in mean value of  HIV+ on treatment (2.12 ± 0.08) when 
compared with treatment naïve (0.60 ± 0.03).
Different from some patterns above, TC/HDL-C mean value for 
the people with HIV + on treatment (4.40 ± 0.27) was significantly 
increased (p < 0.05) than both treatment naïve (2.99 ± 0.09) and 
controls (3.77 ± 0.09). Also, LDL/HDL-C mean value for the 
people with HIV+ on treatment (2.44 ± 0.21) was significantly 
higher (p < 0.05) than both groups of  treatment naïve (0.73 ± 
0.05) and controls (2.39 ± 0.09). In addition, the CD4 cell count 
mean value of  the people with HIV+ on treatment (468.83 ± 
19.48) was significantly higher (p < 0.05) than for HIV+ group 
of  treatment naïve (183.55 ± 21.79) but significantly less than 
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the controls (886.60 ± 12.62). No significant value (p < 0.05) 
was recorded comparing the mean value of  age (years) in HIV+ 
patients on treatment (33.73 ± 1.26) with treatment naïve (37.23 
± 1.39) and the controls (34.10 ± 1.35).
Table 2 shows correlation of  parameters within a group of  
patients with HIV+ on treatment, significant positive correlations 
were observed within the group pairs of  analytes as follows; TC 
and LDL-c (r = 0.844, P < 0.01), TC and LDL/HDL-c ratio (r = 
0.359, p < 0.05), TG and TC/HDL-c ratio (r = 0.358, p < 0.05), 
HDL-c and LDL-c (r = 0.472, p < 0.01), HDL-c and TC/HDL-c 
(r = 0.865, p < 0.01), HDL-c and LDL/HDL-c (r = 0.853, P 
< 0.01), LDL-c and TC/HDL-c (r = 0.634, p < 0.01), LDL-c 
and LDL/HDL-c (r = 0.710, p < 0.01), LDL and CD4+ count 
(r = 0.344, p < 0.01), and TC/HDL-c and LDL/HDL-c ratios 
(r = 0.993, p < 0.01) respectively. While a significant negative 
correlation was observed in TG and CD4+ cell count (r = -0.507, 
p < 0.01) level.
Table 3 shows correlation of  parameters within a group of  patients 
with HIV+ treatment naïve, significant positive correlations were 
observed within the group pairs of  analytes as follows; LDL-c 
and TC/HDL-c (r = 0.771, p < 0.01), LDL-c and LDL/HDL-c (r 
= 0.915, p < 0.01), as well as TC/HDL-c and LDL/HDL-c ratios 
(r = 0.780, p < 0.01) respectively. However, significant negative 
correlations were observed in TG and CD4+ cell count (r = 
-0.380, p < 0.05) level, HDL-c and LDL-c (r = -0.730, p< 0.01), 
HDL-c and TC/HDL-c ratio (r = -0.703, p < 0.01) as well as 
HDL-c and LDL/HDL-c ratio (r = -0.787, p < 0.01) respectively.
Table 4 shows correlation of  parameters within a group of  
apparently healthy controls. Significant positive correlations were 
observed within the group as follows; TC and HDL-c (r = 0.484, 
p < 0.01), TC and LDL-c (r = 0.742, p < 0.01), LDL and TC/
HDL-c ratio (r = 0.676, p < 0.01), LDL-c and LDL/HDL-c ratio 
(r = 0.746, p < 0.01), TC/HDL-c and LDL/HDL-c (r = 0.984, p 
< 0.01) ratios. While negative associations were observed between 
TG and LDL-c (r = -0.421, p < 0.01), TG and LDL/HDL-c ratio 
(r = -0.454, p < 0.01), HDL-c and TC/HDL-c (r = -0.733, p < 
0.01) as well as HDL-c and LDL/HDL-c (r= -0.682, p < 0.01) 
respectively.
Figure 1 shows effects of  HIV infection on body lipid 
and lipoprotein levels and their typical changes following 
commencement of  ART treatments. HIV infection revealed rise 
in TG and reductions in other lipoparticles. However, in the case 
of  ART treatments, there was an improved HDL-c level but with 
associated increases in TC, TC/HDL-c, LDL/HDL-c and LDL-c 
levels.
Discussion
In this present study, a significant increase in triglyceride level and 
significant lowered values in total cholesterol, HDL-C, LDL-C, 
TC/HDL-C and LDL-C/HDL-C ratios with CD4 cell counts 
were observed in HIV infected subjects (not yet on treatment) 
compared with HIV-negative subjects.
This agrees with the findings of  [33] which states that patients in 
HIV infection were reported to have hypocholesterolaemia with 
and sometimes without hypertriglyceridaemia. Also, [39] reported 
similar findings with this study in which there were significantly 
low levels of  total cholesterol, HDL and LDL in HIV infected 
patients, and about 40% of  HIV-infected subjects were reported to 
be hypocholesterolemic when compared to seronegative controls. 
This low level of  total cholesterol, HDL and LDL, was described 
to be associated with elevated level of  β-2 microglobulin. Low 
cholesterol levels are prevalent even during the early stages of  
HIV and associated with a specific alteration in immune function. 
Consistent with earlier reports, this study also showed similar 
finding [22] with another study in which the decrease of  CD4+ 
Table 1. Mean ± SEM of  lipids, lipoparticle levels, CD4 cell count and age for HIV+ patients on treatment, treatment naïve 
and controls using ANOVA and Post Hoc tests.
PARAMETERS GROUP 1
N=40
GROUP 2
N=40
GROUP 3
N=40
F-VALUE P-VALUE
Total cholesterol
(mmol/l)
3.69 ± 0.07a,b 2.43 ± 0.04a 5.32 ± 0.09 469.991 0.001*
Triglycerides
(mmol/l)
1.87 ± 0.03a,b 1.97 ± 0.02a 1.18 ± 0.05 143.924 0.001*
HDL-cholesterol
(mmol/l)
0.99 ± 0.04a,b 0.85 ± 0.02a 1.43 ± 0.04 79.678 0.001*
LDL-cholesterol
(mmol/l)
2.12 ± 0.08a,b 0.60 ± 0.03a 3.32 ± 0.09 406.316 0.001*
TC/HDL-c 4.40 ± 0.27a,b 2.90 ± 0.09a 3.77 ± 0.09 18.628 0.001*
LDL/HDL-c 2.44 ± 0.21b 0.73 ± 0.05a 2.39 ± 0.09 53.559 0.001*
CD4 (cells/µl) 468.83 ± 19.48a,b 183.55 ± 21.79a 886.60 ± 12.62 344.143 0.001*
Age (yrs) 33.73 ± 1.26 37.23 ± 1.39 34.10 ± 1.35 2.075 0.130
KEY: Group 1- HIV positive patients on ART treatment; TC-Total cholesterol.
Group 2 - HIV positive patients (treatment naïve); CD4 - Cluster of  differentiation 
Group 3 - HIV negative patients (controls); HDL - High density lipoprotein; LDL - Low density lipoprotein; *= statistically significant 
(p ≤ 0.05); a = significantly different from controls (Post Hoc); b = significantly different from treatment naïve (Post Hoc).
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count due to disease progression was accompanied by a decrease 
in the total cholesterol, HDL-c, and LDL-c, and an increase in 
triglycerides. This hypertriglyceridemia, was also reported by 
other authors [21, 30] which may be correlated to opportunistic 
infections and to interferon-α. The relationship between 
triglycerides (TG) and interferon-alpha (IFN-α) in HIV-positive 
patients has been previously reported by [22].
In a further study by [20], IFN-α was found to increase TG by two 
main mechanisms: a decrease in TG clearance; and an increase 
of  de novo hepatic lipogenesis and VLDL production. This 
hepatic lipogenesis was related with stimulation by three types 
of  cytokines: tissue necrotic factor- alpha (TNF-α), Interleukins 
1 and 6 ( IL- 1 and IL-6) that increase hepatic levels of  citrate; 
and IFN-α that does not increase hepatic citrate. Both decreased 
TG clearance and increased hepatic VLDL overproduction have 
been found in HIV-positive patients, and the hepatic increased 
lipogenesis correlates to IFN-α [20]. Again, by the level of  
immunological deficiency according to the CD4+ cell count, some 
authors [38, 37, 13] determined the level of  plasma triglycerides, 
total cholesterol and HDL-C in HIV infected individuals and 
came to the same conclusion with an increase in immunological 
deficiency and clinical development of  HIV infection, lipid 
profile disorders-indicated by an increase in triglycerides level and 
decrease concentrations of  HDL-C. 
However, some authors [12, 13] reported contradictory findings 
that patients with AIDS had increased levels of  LDL-c. Also in 
Table 2. Pearson's correlation coefficients of  biochemical parameters in a group of  patients with HIV-positive on 
treatment.
Parameters TC (mmol/l)
Triglyceride 
(mmol/l)
HDL-c
(mmol/l)
LDL-c
(mmol/l)
TC
HDL-c
LDL
HDL-c
CD4
(cells/µl)
TC (mmol/l) 1 -0.005 0.032 0.844** 0.284 0.359* 0.300
 Triglycerides (mmol/l) 1 -0.171 -0.113 0.358* 0.274 -0.507**
HDL-c (mmol/l) 1 0.472** 0.865** 0.853** 0.029
LDL-c (mmol/l) 1 0.634** 0.710** 0.344**
TC/HDL-c 1 0.993** 0.090
LDL/HDL-c 1 0.022
CD4 (cells/µl) 1
*Correlation significant at 0.05 level. **correlation significant at 0.01 level.
Table 3. Pearson's correlation coefficients of  biochemical parameters in a group of  HIV-positive treatment naïve.
 Parameters TC 
(mmol/l)
Triglyceride 
(mmol/l)
HDL-c
(mmol/l)
LDL-c
(mmol/l)
TC
HDL-c
LDL
HDL-c
CD4
(cells/µl)
TC (mmol/l) 1 0.172 -0.005 0.177 0.017 0.191 -0.230
 Triglycerides (mmol/l) 1 0.107 -0.073 -0.024 -0.035 -0.380*
HDL-c(mmol/l) 1 -0.730** -0.703** -0.787** 0.251
LDL-c(mmol/l) 1 0.771** 0.915** -0.199
TC/HDL-c 1 0.780** -0.307
LDL/HDL-c 1 -0.223
CD4 (cells/µl) 1
**correlation significant at 0.01 level, *Correlation significant at 0.05 level 
Table 4. Pearson’s correlation coefficients of  biochemical parameters in apparently healthy controls.
 Parameters TC
(mmol/l)
Triglycerides
 (mmol/l)
HDL-c
(mmol/l)
LDL-c
(mmol/l)
TC
HDL-C
LDL
HDL-C
CD4
(cells/µl)
TC (mmol/l) 1 0.036 0.484** 0.742** 0.229 0.278 0.024
Triglycerides (mmol/l) 1 0.286 -0.421** -0.308 -0.454** -0.324
HDL-c (mmol/l) 1 -0.096 -0.733** -0.682** 0.454
LDL-c (mmol/l) 1 0.676** 0.746** -0.215
TC/HDL-c 1 0.984** 0.372
LDL/HDL-c 1 0.272
CD4 (cells/µl) 1
**correlation significant at 0.01 level, *Correlation significant at 0.05 level.
Kamoru AA, Japhet OM, Adetunji AD, Akinlawon AA, Musa MA, et al., (2017) CD4+ Cell Count, Lipid And Lipoprotein Levels In Hiv Patients On Drug Treatment. Int J AIDS 
Res. 4(1), 140-146. 145
 OPEN ACCESS                                                                                                                                                                                  http://scidoc.org/IJHR.php
another report [14], higher total cholesterol was noted in subjects 
with associated AIDS-defining events, which contradicted these 
findings.
Furthermore, in this present study the effect of  ART treatment 
on lipid profile as well as CD4+ cell count was drawn between 
the HIV-positive on ART treatment and HIV-positive not on 
treatment and a significantly reduced value in triglycerides with 
significant increases in total cholesterol, HDL-c, LDL-c, and TC/
HDL-c and LDL/HDL-c ratios with CD4 count were observed.
This is corroborated by the result of  [36] also supported by Gilead 
903 studies, where it was stated that HAART subjects' median 
total cholesterol was significantly higher than the patients who 
were not on HAART, but was not different than those who were 
HIV uninfected. The same pattern was further noted in this study 
[36] for LDL cholesterol: women on HAART had been reported 
with higher levels than those who were HIV infected and not 
on treatment, but similar levels to uninfected women. Median 
high-density lipoprotein (HDL) cholesterol was higher in the 
HIV-uninfected women than in untreated HIV-infected women, 
although this was not significantly different from the median level 
of  HAART recipients. 
Certainly, other predominantly male studies, including [42, 49] 
and Gilead 903 studies, have demonstrated an increase in HDL 
cholesterol after NNRTI treatment therefore these results are 
congruent with what has been seen in men. This study, rather than 
identifying gender differences, supports a similar lipid response in 
men and women after HIV infection and HAART initiation and 
therefore agrees with our present study of  combined gender in 
our participants. On the contrary, triglyceride levels were reported 
as highest in the HAART group; this was greater than among the 
HIV-uninfected women but not the untreated group, which partly 
contradicted our current finding.
It is crystal clear from the findings above that the concentrations 
of  total cholesterol and LDL-c increase, following the initiation 
of  treatment, surpassed the HDL-c level, and therefore call for 
assessment of  possible risk factors of  cardiovascular disease 
(CVD) in view of  standpoints of  TC/HDL-c as well as LDL-C/
HDL-c ratios. Also, according to [50], LDL-C is reported to have 
positive correlation with incidence of  cardiovascular disease with 
nearly 75% of  the plasma cholesterol incorporated into the LDL 
particles and possibly lead to myocardial infarction. From our 
present study, the ratios of  both TC/HDL-c and LDL/HDL-c 
were found significantly increased. According to [43], an increase 
in TC/HDL-C is a pointer to coronary artery disease. Likewise, 
an increase in LDL-c is an atherogenic lipid marker while TC/
HDL-c and LDL/HDL-c ratios (atherogenic indices) have been 
attributed with more predictive power of  cardiovascular risk 
[34]. Similarly, as TC/HDL-c is considered a more sensitive and 
specific index of  cardiovascular risk than total cholesterol, this 
lipid ratio has been selected by the Canadian working group as a 
secondary goal of  therapy [17].
Conclusion
With abnormal lipid profile findings in the present study, it shows 
that both HIV infection and ART treatment may cause metabolic 
alterations, however, the risk predictors, often termed atherogenic 
indices (TC/HDL-c and LDL/HDL-c ratios) were more 
noticeable in ART treatment and this may threaten a significant 
risk of  developing cardiovascular disease.
Reccomendations
To further studies on the role of  ART, differentiated from 
HIV infection, in the pathogenesis of  metabolic syndrome 
and cardiovascular disease a multivariable analysis involving 
measurements of  apo C-111, apo-E, liver enzymes, and 
heamatological parameters such as C-reactive protein and platelet 
count, probably involving multiracial or multinational dimension 
is needed. This is to further explore possible association of  these 
biomarkers with liver function in apolipoprotein synthesis as well 
as inflammatory reactions.
However, researchers would continue to be at variance if  individual 
ARV agents are not well studied rather than combination therapy, 
Figure 1. Bar Chart Showing Mean Distributions of  Various Parameters in Patient and Control Groups.
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before their reports put side by side.
Also and importantly, physicians should take note of  possible 
toxicity associated with HAART especially for patients with 
underlying and predisposing factors before prescription and 
regimen are addressed. 
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